Showing results (131-140 of 168) with videos related to

Sort By:
Pageof 17
HIV Medicine|November 21, 2008
Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppressionC J Smith, A N Phillips, B Dauer, et al.
Antiviral Therapy|June 10, 2000
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohortV Miller, A Cozzi-Lepri, K Hertogs, et al.
AIDS (London, England)|December 12, 2001
Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individualsA N Phillips, V Miller, C Sabin, et al.
Haematologica|June 15, 2007
First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemiaT Wolf, V Rickerts, S Staszewski, et al.
JAMA|July 10, 1996
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working GroupC Katlama, D Ingrand, C Loveday, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 1, 1990
[Prospective study of primary and secondary prevention of Pneumocystis carinii pneumonia with pentamidine aerosol]S Staszewski, S Trinder, A Gottstein, et al.
Infection|November 1, 1996
Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patientsP M Shah, A Heller, H G Fuhr, et al.
AIDS (London, England)|August 16, 2001
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNAN Clumeck, F Goebel, W Rozenbaum, et al.
The Journal of Infectious Diseases|July 9, 1999
CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus loadV Miller, S Staszewski, C Sabin, et al.
AIDS (London, England)|June 17, 1999
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapyS Staszewski, V Miller, C Sabin, et al.
Pageof 17